Value of orthostatic hypotension as a prognostic bedside test in heart failure

Tarek M. Abdel Rahman

Department of Cardiology, El Minia University Hospital, Egypt. E-mail: tarekabelrahman2@yahoo.com.

Received 20 October, 2012; Accepted 09 December, 2012

Orthostatic hypotension (OH) has been linked to increased mortality and incidence of cardiovascular disease in various risk groups. Our aim is to identify the determinants and consequences of OH in the heart failure population as this was poorly studied. Sixty-Four patients with known history of heart failure were collected. Grouping is based upon whether they have (OH) or not. Group-A found to have normal BP response to standing; they were 24 patients (18 male and 6 female) of mean age (45 ± 8 years), Group-B discovered to have significant (OH) and was 22 patients (16 males and 6 females) of mean age (43 ± 4 years). The first clinical and echocardiographic examination was done and considered as a base-line characteristic. Then, a call-back after 6 months for follow-up and second visit examination is recorded. In the first visit, comparison of data revealed no significant variations. In the second visit (6-month later), divergence of data is observed and was statistically significant. Group-B was found to have a lower EF and FS% (p=0.01), a lower Dp/Dt (p=0.01) and a higher Tie-Index and MR-jet area (p=0.01). Indeed, the questionnaire proved frequent times of hospital admissions, paroxysmal nocturnal dysnea, need for treatment modification, arrhythmias and lower limb edema in group-B. The present study conclude that, heart failure-patients having orthostatic hypotension experienced a significant deterioration of clinical condition and cardiac functions along a period of six months which represent failure in their autonomic compensatory mechanisms and possible impact on their mortality.

Key words: Orthostatic hypotension, heart failure.

INTRODUCTION

The central blood volume is abruptly reduced when one stands up. A complex set of compensatory physiological mechanisms then occur to maintain the upright posture. These include reflex responses in the cardiovascular and autonomic nervous systems as well as activation of the skeletal muscle and respiratory pumps. As a result, rapid changes in arterial blood pressure occur (Goldstein and Shapiro, 1995). In population studies, the systolic blood pressure (SBP) response to a change in posture is approximately normally distributed with a mean close to 0 mm Hg, but the range includes SBP decreases and increases of considerable magnitude (Nardo et al., 1999).

Orthostatic hypotension (OH) occurs when there is a marked decrease in blood pressure after the upright posture is assumed. Although previously not consistently defined, guidelines established in the 1990s suggested defining OH as a decrease in SBP ≥20 mm Hg and/or a decrease in diastolic blood pressure (DBP) ≥10 mm Hg (The Consensus Committee of the American Autonomic Society and the American Academy of Neurology, 1996). In middle-aged persons in the Atherosclerosis Risk in Communities (ARIC) Study, OH has been associated with incident hypertension, coronary heart disease (CHD), (Rose et al., 2002) and stroke (Eigenbrodt et al., 2000). Several studies have examined the association between OH and mortality in the elderly or other high-risk populations. Some have reported a modest increased risk of mortality among those with OH, (Luukinen et al., 2004; Rose et al., 2002; Eigenbrodt et al., 2000) whereas others have reported no association (Luukinen and Airaksinen, 2005).

Orthostatic blood pressure (BP) control involves complex compensatory mechanisms allowing the human body to stand upright (Smith et al., 1994). As the postural homeostasis is principally mediated by autonomic nervous system, its impairment may lead to BP fall after standing. The phenomenon, denominated as orthostatic hypotension (OH), is often associated with debilitating symptoms: fatigue, dizziness, and fainting (Mathias and Kimber, 1999). Orthostatic hypotension has been defined...
by the international consensus as a decrease in systolic BP ≥ 20 mmHg and/or decrease in diastolic BP ≥ 10 mmHg within 3 min of standing (The Consensus Committee of the American Autonomic Society and the American Academy of Neurology, 1996). In addition, some authors have proposed standing systolic BP < 90 mmHg as an alternative criterion (Alcocock et al., 2006).

Clinicians are usually interested in diagnosing OH as it can cause fall-related injuries, substantially limit patients’ quality of life, (Gates et al., 2008) and finally, impede relevant treatment of concomitant diseases as hypertension or heart failure (Weber et al., 2005). In parallel, relatively little is known about prognostic aspects of OH. Increased mortality and incidence of cardiovascular disease (CVD) related to prevalent OH has been reported in different high-risk groups with dominantly symptomatic patients. However, the number of studies regarding the prognostic value of younger and mainly asymptomatic individuals without significant burden of co-morbidities is limited. Prospective data from the Atherosclerosis Risk in Communities (ARIC) study suggest that OH may confer higher risk of all-cause mortality and cardiovascular events (Luukinen et al., 2004; Rose et al., 2000, 2006; Eigenbrodt et al., 2000).

Cardiovascular autonomic neuropathy (CAN) is progressive and starts without symptoms. The presymptomatic state is defined as “autonomic dysfunction” (AD). As (AD) increases in severity, it leads to peripheral autonomic neuropathy, then diabetic autonomic neuropathy (DAN), and, finally, symptoms associated with end-organ failure. This final stage is also known as CAN (Vinik et al., 2005).

In patients with diabetes, autonomic assessment is often based on three time-domain heart rate variability (HRV) ratios: the exhalation/inhalation (E/I) ratio from a deep breathing challenge, the Valsalva ratio, and the 30:15 ratio from an upright posture challenge (Shin et al., 2004). DAN is indicated if two of the three ratios are abnormally low. CAN is indicated if all three ratios are low. DAN is a risk factor for CAN, and both DAN and CAN are associated with blood pressure (BP) anomalies, including orthostatic hypotension (OH) (Vinik et al., 2003; Grundy et al., 1999). Orthostatic hypotension is one of the most incapacitating symptoms of autonomic failure, including CAN, (Freeman, 2003) and may be used as a marker for CAN. In diabetes and other chronic diseases, AD and CAN are also associated with orthostatic symptoms. Orthostasis presents earlier in patients with diabetes than in those without (Aysin et al., 2006). The earlier onset of orthostasis is partly due to the fact that diabetes can accelerate AD and therefore CAN onset. There is a wide variability in the diagnosis of orthostasis, especially in earlier stages when therapy can be lower dose and shorter term (Arora et al., 2007).

Orthostasis may be difficult to detect and diagnose because both autonomic nervous system (ANS) branches are actively changing in a coordinated fashion during a normal response to postural change: the parasympathetics decrease or withdrawal and the sympathetics increase or surge (Freeman, 2003; Arora et al., 2007; Borst et al., 1982). Therefore, diagnosing orthostasis requires a test that independently and simultaneously measures the response of both ANS branches, the sympathetic nervous system and the parasympathetic nervous system. Because CAN is treatable in all stages and because orthostasis is often treatable in parallel with the other effects of AD, (Maule et al., 2003) the American Diabetes Association and the American Heart Association have recommended testing diabetic patients more than once per year to detect symptoms as early as possible to slow progression of AD (Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, 1996; Aring et al 2005).

MATERIALS AND METHODS

The study was carried out in the Cardiology Department of El- Minia University Hospital from the period of 1st January to 1st September 2011. Patients were recruited from outpatient clinic and archived as regards their names, telephone number, address, and results of their clinical examination to be stored as a base-line data, and then advised to follow-up after 6 months. Data were obtained and computed for easy comparing the data of their examination.

Study population

Selection criteria

These criteria were to choose patients known as or first discovered to have symptoms and signs of cardiac decompensation and diagnosed as idiopathic or Ischaemic heart failure based on Echocardiography. A 46 patients were collected with mean age (44 ± 6 years old). All patients taking the fixed regimen of 4 drugs (diuretic, ACE inhibitor, Digitalis and B-blocker) in appropriate tolerated doses for 15 days and then the first examination was done and considered as a base-line characteristic. Then, a call-back after 6 months for follow-up and second visit examination is recorded.

Exclusion criteria

Exclusion criteria were valvular, congenital, pericardial and hypertensive heart failure. Frail patients or poor health individuals are excluded. Co morbidities (CHD, stroke, cancer, Epileptic seizures, hypertension, diabetes,
or a self-reported fair/poor health status) are also excluded from the study population. None of them taking specific drugs such as (centrally acting drugs, tri-cyclic antidepressant, anti-hypertensive or hypoglycemic agents, cold remedies or thyroid related agents). None of them is current smoker.

All patients were examined as (full-history taking, ECG, general and cardiac examination). Echocardiography was done and the following data were obtained (LA and Lv dimensions, EF and FS%, Dp/Dt in msec, Tei index and MR jet area).

LA Dimension: internal chamber dimensions are taken from parasternal long axis view from the leading the leading edge to trailing edge as shown in Figure 1.

Lv Dimensions, FS% and EF%: are taken from M-Mode in Parasternal long axis view from the trailing edge to leading edge as shown in Figure 2.

Dp/Dt: is the rate of pressure rise inside left ventricle and is taken from the MR in continuous Doppler mode of the sample volume adjusted in the center of MV orifice as shown in Figure 3.

Tei-Index: is the Index of myocardial performance which is devised to incorporate both systolic and diastolic time intervals in expressing global ventricular performance. Systolic dysfunction results in a prolongation of the pre-ejection time (IVCT) and a shortening of the ejection time (ET). Both systolic and diastolic dysfunction results in abnormality in myocardial relaxation, which prolongs the relaxation period (IVRT). So, Tei-Index = (IVCT+IVRT)/ET. Normal value is 0.39±0.05 as shown in Figure 4.

MR jet area: is measured in tracing the color-jet of MR in systole by two methods (parasternal and 2D) after adjusting the aliasing and...
Nyquist limit in colored Mode and averaged as shown in Figure 5.

Data were averaged in patients with atrial fibrillation rhythm. After a period of six months, all data of the patients were compared for each patient in relation to his individual baseline data. In addition each patient advised to report changes in his clinical symptoms in a note-book describing five main items to answer a questionnaire at the end of the study involves (times of admission to hospital, need for treatment modification, numbers of paroxysmal nocturnal dysnea, numbers of arrhythmic episodes and manifest lower limb edema).

**Measurement and classification of blood pressure response to a change in posture**

We used two methods to measure supine and standing blood pressure. First, was automated blood pressure measurements which was taken approximately every 30 s for 2 min (range of 2 to 5 measurements; 90% had at least 4 measurements). Participants were then asked to stand, and as their feet touched the ground, a standing blood pressure measurement was taken. Measurements were repeated during the first 2 min after standing (range of 2 to 5 measurements).

Because blood pressure restabilization is still occurring during the first 30 s after standing, (29) blood pressure change was defined as the difference between the average of the standing and the supine blood pressure measurements, excluding the first standing measurement. With the use of established guidelines, (3) participants were classified by the presence (a decrease of at least 20 mm Hg SBP or a decrease of at least 10 mm Hg DBP) or absence of OH.

Second reading was obtained in another setting in the same hour, after doing the Echocardiography in which the blood pressure (mmHg) was re-measured auscultatory by specially trained nurses in two different positions (supine and standing), with a mercury sphygmomanometer and an appropriate cuff placed around the right arm. First BP reading was taken after 10 min rest in the supine position. Then the participants were asked to stand up and the second BP measurement was taken after 1 min. Blood pressure was determined and recorded to the nearest 5 mmHg. The final record was through approximation of each figure to another, but, if marked difference > 10 mmhg, the auscultatory method is chosen.

**Definition of orthostatic hypotension**

Orthostatic hypotension at the baseline was defined according to the international consensus (The Consensus Committee of the American Autonomic Society and the American Academy of Neurology, 1996) as a decrease in systolic BP ≥ 20 mmHg and/or decrease in diastolic BP ≥10 mmHg within 3 min of standing, or, in addition, as standing systolic BP <90 mmHg.

**Study grouping**

Patient's data were collected and results of blood pressure response to standing classify the patients into two groups: individuals with a normal response to standing (OH-negative) were defined as Group-A and individuals with orthostatic hypotension (OH-positive) were defined as Group-B. The group-A were 24 patient of mean Age (45 ± 8 y) and group-B were 22 patient of mean Age (43±4 y).

Clinical and Echocardiographic data were compared in relation to base-line and 6-months follow up results. Moreover, questionnaire is applied and their answers were also compared.

**RESULTS**

Clinical data were compared as regards the base-line between group-A and group-B and revealed no significant variations as shown in Table 1.

Also, Echocardiographic data were compared in the first visit between group-A and group-B and revealed no significant variations as shown in Table 2.

Echocardiographic data were compared between base-line features and 6-months follow-up visit and revealed a significant deterioration in group-B in the form of reduction in EF and FS%, reduced Dp/Dt, prolongation of Tei-Index and increased MR-jet area in group-B in relation to group-I as shown in Table 3.

Graphic presentations of the echocardiographic results
Table 1. Clinical data were compared as regards the base-line between group-A and group-B.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group-A</th>
<th></th>
<th></th>
<th></th>
<th>Group-B</th>
<th></th>
<th></th>
<th></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td></td>
<td>Mean</td>
<td>SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>45</td>
<td>8</td>
<td>43</td>
<td>4</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>18</td>
<td>16</td>
<td></td>
<td></td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>28.2</td>
<td>2.6</td>
<td>26.8</td>
<td>4.8</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA-class</td>
<td>2.6</td>
<td>0.64</td>
<td>2.8</td>
<td>0.44</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic Bp</td>
<td>118.1</td>
<td>14.8</td>
<td>116.2</td>
<td>15.2</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate</td>
<td>95.2</td>
<td>10.0</td>
<td>96.2</td>
<td>8.8</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Echocardiographic data compared in the first visit between group-A and group-B.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group-A</th>
<th></th>
<th></th>
<th></th>
<th>Group-B</th>
<th></th>
<th></th>
<th></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td></td>
<td>Mean</td>
<td>SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EF%</td>
<td>40.2</td>
<td>2.5</td>
<td>39.5</td>
<td>1.9</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FS%</td>
<td>20.4</td>
<td>1.4</td>
<td>19.8</td>
<td>1.3</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dp/Dt</td>
<td>742.3</td>
<td>22.6</td>
<td>652.3</td>
<td>10.7</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tei-Index</td>
<td>0.54</td>
<td>0.18</td>
<td>0.62</td>
<td>0.08</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MR-jet area</td>
<td>3.32</td>
<td>0.16</td>
<td>3.4</td>
<td>0.12</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Echocardiographic data between groups after 6-month.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group-A</th>
<th></th>
<th></th>
<th></th>
<th>Group-B</th>
<th></th>
<th></th>
<th></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td></td>
<td>Mean</td>
<td>SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EF%</td>
<td>41.0</td>
<td>2.2</td>
<td>38.2</td>
<td>1.6</td>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FS%</td>
<td>20.8</td>
<td>1.6</td>
<td>18.4</td>
<td>1.1</td>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dp/Dt</td>
<td>762.1</td>
<td>23.5</td>
<td>644.3</td>
<td>40.2</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tei-Index</td>
<td>0.48</td>
<td>0.13</td>
<td>0.71</td>
<td>0.18</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MR-jet area</td>
<td>3.55</td>
<td>0.14</td>
<td>4.2</td>
<td>0.21</td>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

display this deterioration at the end of the study as shown in Figures 6, 7 and 8.

Moreover, answers of the questionnaire at the end of the study revealed that, Group-B who were positively having orthostatic hypotension experienced frequent admission to hospital, frequent attacks of PND and palpitations. Also, observed increased times of manifest lower limb edema and need many times to increased their diuretic doses as shown in Table 4.

**DISCUSSION**

Cardiovascular autonomic neuropathy (CAN) is progressive disease and starts without symptoms. The pre-symptomatic state is defined as “autonomic dysfunction” (AD). Orthostatic hypotension is one of the most incapacitating symptoms of autonomic failure, including CAN, (Applegate et al., 1991) and may be used as a marker for CAN. In diabetes and other chronic diseases, AD and CAN are also associated with orthostatic symptoms (Luukinen et al., 2004).

There is a wide variability in the diagnosis of orthostasis, Orthostasis may be difficult to detect and diagnose because both autonomic nervous system (ANS) branches are actively changing in a coordinated fashion during a normal response to postural change: the parasympathetics decrease or withdrawal and the sympathetics increase or surge. Therefore, diagnosing orthostasis requires a test that independently and
simultaneously measures the response of both ANS branches, the sympathetic nervous system and the parasympathetic nervous system (Luukinen et al., 2004).

Most research on OH is based on elderly, frail populations in which OH is accompanied by symptoms of dizziness and syncope and is associated with falls, fractures, and potential serious morbidity. Recent evidence suggests that OH in the elderly is associated with decreases in vestibular function. OH is consistently associated with older age, elevated blood pressure, and thicker carotid arterial walls. Inconsistent associations are noted between OH and body mass index (BMI), diabetes, and cigarette smoking. Few prospective studies have investigated the association between OH and cardiovascular disease outcomes (Ray and Monahan, 2002; Shin et al., 2004). Research studies should be directed towards patients with known structural heart pathology after excluding other non-specific factors and its implication on prognosis and outcome of these cardiac diseases, our study aiming to put idea on this value choosing heart failure as a variant of cardiac patients having much more incapacitations and short life span.

Our results were promising through identifying the group of heart failure patients experienced (OH) in their blood pressure recordings and confirmed a much more deterioration in their clinic or echocardiographic features. The group-A showed significant higher EF, FS% and Dp/Dt than Group-B after six months, in spite of, being nearly similar in the first visit and this finding was identical to the results of Almoznino et al. (2009) who reports the same findings and recommends the idea of using leg compression bandaging thinking of that is may be useful for prevention of postural hypotension in these patients (Almoznino et al., 2009).

Recently, in a Swedish prospective cohort study done over a period of 24 years by Fedorowski et al. (2011) discovered the idea of effect of (OH) in determining the course and outcome of heart failure deterioration. The study concluded that, the incidence of first hospitalization and new-onset HF was related to early postural changes in systolic and diastolic blood pressure and prove that early increase of blood pressure in response to orthostatic challenge signals reduced the risk of HF development (Fedorowski et al., 2011).

Before one year the same author detect the link between (OH) and all cause mortality as, Orthostatic hypotension can be detected in 6% of middle-aged individuals and is often associated with such comorbidities as hypertension or diabetes. Presence of OH increases mortality and CE risk, independently of traditional risk factors. Although both impaired systolic and diastolic responses predict adverse events, the diastolic impairment shows stronger association with coronary disease (Fedorowski et al., 2010).
Also, Potocka et al. (2001) confirmed that, CHF patients showed a decreased ability to develop compensatory tachycardia during hypotension. Moreover, reduction in systolic blood pressure was more pronounced in CHF patients, and diastolic blood pressure increase was less significant as compared with his control group (Potocka-Plazak and Plazak, 2001).

Our study revealed more clinical deterioration in group-B in the form of frequent hospitalizations and need for intensifying medical treatment with recurrent attacks of orthopnea and arrhythmias. This is coincident with data published by Ahmed et al. (2008) who study the effect of recurrent hospitalizing of heart failure patients on the mortality, they found that, incident hospitalization due to worsening HF was associated with significant increase in all-cause and cardiovascular mortality in a wide spectrum of ambulatory patients with chronic mild to moderate systolic and diastolic HF (Ahmed et al., 2008).

These findings highlight the importance of HF hospitalization as a marker of disease progression and poor outcomes in HF, and emphasize on the need for prevention of HF hospitalization, and treatment strategies for hospitalized HF patients to improve post-discharge outcomes. These findings are important, as worsening HF is the number one reason for hospitalization for HF patients.

HF is a progressive disorder with poor prognosis. Common identifiable causes of HF hospitalizations include acute coronary syndrome, uncontrolled hypertension, arrhythmias and use of anti-arrhythmic drugs, pulmonary infections, and noncompliance with medications and diet. There is cumulative evidence that serum troponin levels may be elevated in HF, which in turn may be associated with worsening HF, HF hospitalization, and mortality. Elevated serum troponin levels in acute HF have been associated with increased risk of subsequent mortality and hospitalizations. Other explanations for poor post-discharge outcomes include bed rest and restricted mobility during hospitalizations (Gheorghiade et al., 2005; Schiff et al., 2003; Perna et al., 2005).

In the SOLVD trial, the survival benefit of Enalapril was observed only among the patients who were hospitalized at least once during the trial. Because treatment effects often depend on severity or stage of disease, a history of HF hospitalization may be used as inclusion criteria in future HF trials.

This is important as event rates in contemporary systolic HF patients receiving optimal therapy and in those with diastolic HF (clinical HF with normal or near normal ejection fraction) are expected to be low. Future studies are needed to investigate whether cardiac resynchronization therapy during hospitalization and the prescription of beta-blockers at the time of hospital discharge might favorably reduce post-discharge mortality compared to patients without HF hospitalizations (The SOLVD Investigators, 1991).

As a recent post-ho analysis of CHARM database demonstrated that post base-line “discharge for first hospitalization for HF” was independently associated with increased mortality (Rothwell, 2005).

In a paradigm of using a simple clinical questionnaire in our study to identify the risk among patients of HF, a large study made by Mikhail et al. (2007) confirmed the risk between deterioration in clinical symptoms of HF-patients and mortality in the expanded project of "health service and outcome research" using the famous Kansas City cardiomyopathy questionnaire through follow up 1358 patients of chronic HF and defined a definite relation between recurrent hospitalization, frequent orthopnea and lower limb swelling on reduction of life span and increased mortality (Mikhail et al., 2007).

**LIMITATIONS OF THE STUDY**

Like any non-randomized study, propensity score analysis cannot account for confounding due to unmeasured covariates. However our sensitivity analysis suggests that, our findings were rather insensitive to hidden biases.

We are able to find near exact-matching for most of patients with HF-hospitalization. Also, in spite therapy for systolic HF has evolved since the DIG trial was conducted, we did not clarify the effect of therapy on HF-outcome and mortality and we had no data on use of beta-blockers, diuretic dosages and aldosterone antagonists is another limitation in our study. Indeed, the main crucial point in our study is relatively small number of cases and a short-term follow up. Moreover, we did not directly estimate the exact number and percentage of mortality in our patients.

**Table 4. Answers of the questionnaire.**

<table>
<thead>
<tr>
<th>Question</th>
<th>Group A</th>
<th>Group B</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numbers of admission to hospital?</td>
<td>2</td>
<td>6</td>
<td>0.001</td>
</tr>
<tr>
<td>Attacks of paroxysmal nocturnal dysnea?</td>
<td>0</td>
<td>3</td>
<td>0.001</td>
</tr>
<tr>
<td>Need for treatment modifications?</td>
<td>1</td>
<td>4</td>
<td>0.001</td>
</tr>
<tr>
<td>Attacks of arrhythmias or palpitations?</td>
<td>1</td>
<td>4</td>
<td>0.001</td>
</tr>
<tr>
<td>Manifest lower limb edema?</td>
<td>1</td>
<td>6</td>
<td>0.001</td>
</tr>
</tbody>
</table>
REFERENCES


Aysin B, Aysin E, Colombo J, Vinik A (2006). Diabetes may accelerate the onset of orthostasis. 6th Annual Diabetes Technology Meeting; Nov. 2–6; Atlanta, GA.


